MedElevator
Войти в исследования Journal of clinical psychopharmacology · 2026
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Interactions Between Alcohol and Sunobinop in Healthy Participants.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Harris Stephen C, Shet Manjunath S, Cipriano Alessandra, Whiteside Garth T, He Ellie, Zhou Mingyan, Kapil Ram P, Apseloff Glen
Аннотация
BACKGROUND: Sunobinop is a potent, selective partial agonist at nociception/orphanin-FQ receptors with therapeutic potential in a variety of clinical disorders. This study assessed safety, tolerability, pharmacodynamics, and pharmacokinetic interactions of sunobinop and alcohol in healthy adults.
METHODS: This was a single-center, randomized, blinded, crossover study in 48 participants. Single doses of placebo, sunobinop 2 mg (therapeutic), and 6 mg (supratherapeutic), were administered in the morning with alcohol or placebo. Pharmacokinetic and pharmacodynamic profiles were compared.
RESULTS: Coadministration with alcohol did not alter the pharmacokinetics of alcohol or of sunobinop at either dose. A dose-effect relationship in the magnitude/duration of impairment in psychomotor/cognitive parameters was observed, with transient additive effects at 2 mg and greater-than-additive effects at 6 mg that resolved by 5 hours post administration. The most common treatment-emergent adverse event was somnolence, which was mild to moderate.
CONCLUSIONS: A single oral dose of sunobinop was safe and tolerated alone and in combination with alcohol. No pharmacokinetic interaction between sunobinop and alcohol was observed. An additive or greater-than-additive effect was observed for psychomotor/cognitive measures consistent with sunobinop's sleep-promoting effect, and would peak and resolve during a typical night's sleep.
METHODS: This was a single-center, randomized, blinded, crossover study in 48 participants. Single doses of placebo, sunobinop 2 mg (therapeutic), and 6 mg (supratherapeutic), were administered in the morning with alcohol or placebo. Pharmacokinetic and pharmacodynamic profiles were compared.
RESULTS: Coadministration with alcohol did not alter the pharmacokinetics of alcohol or of sunobinop at either dose. A dose-effect relationship in the magnitude/duration of impairment in psychomotor/cognitive parameters was observed, with transient additive effects at 2 mg and greater-than-additive effects at 6 mg that resolved by 5 hours post administration. The most common treatment-emergent adverse event was somnolence, which was mild to moderate.
CONCLUSIONS: A single oral dose of sunobinop was safe and tolerated alone and in combination with alcohol. No pharmacokinetic interaction between sunobinop and alcohol was observed. An additive or greater-than-additive effect was observed for psychomotor/cognitive measures consistent with sunobinop's sleep-promoting effect, and would peak and resolve during a typical night's sleep.